[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ospedale San Raffaele\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":207},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,73,95,125,148,181],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100629781","production-of-stem-cells-for-the-generation-of-pancreatic-cells-100629781",false,"NCT07479134","Production of Stem Cells for the Generation of Pancreatic Cells","Production Of Induced Pluripotent Stem Cells (iPSCs) For The Generation Of Insulin-Producing β Cells","Inclusion Criteria:\n\nAge between 12 and 70 years.\n\nAbility and willingness to provide informed consent (or assent with parental consent for minors).\n\nGroup 1: Individuals diagnosed with pancreatic β cell dysfunction, including but not limited to:\n\nType 1 Diabetes\n\nType 2 Diabetes\n\nMaturity Onset Diabetes of the Young (MODY)\n\nWolfram Syndrome\n\nPancreatogenic Diabetes\n\nGroup 2: Healthy control donors without pancreatic β cell dysfunction.\n\nPregnant or breastfeeding women may be included if they meet the inclusion criteria.\n\nExclusion Criteria:\n\nAge below 12 or above 70 years.\n\nHealth condition too compromised to allow safe tissue collection (e.g., acute hypoglycemia \\\u003C70 mg\u002FdL or hyperglycemia \\>140 mg\u002FdL at sampling).\n\nInability or unwillingness to provide informed consent\u002Fassent.\n\nActive malignancy or current cancer treatment.\n\nKnown infection with HIV, Hepatitis B, or Hepatitis C.\n\nUse of medications that may interfere with iPSC generation (e.g., high-dose corticosteroids, immunomodulators), unless approved by investigators.\n\nFor participants undergoing skin biopsy: bleeding disorders, local skin infection, allergy to anesthetics, or use of anticoagulants.",true,"ALL","12 Years","70 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this interventional study is to generate induced pluripotent stem cells (iPSCs) from somatic cells and differentiate them into insulin-producing β cells in patients with metabolic and genetic pancreatic diseases and in healthy controls. The main questions it aims to answer are:\n\nCan somatic cells from healthy individuals and patients with diabetes be successfully reprogrammed into iPSCs?\n\nCan these iPSCs be differentiated into functional insulin-producing β cells suitable for studying disease mechanisms and developing cell-based therapies?\n\nParticipants will provide a single biological sample (either a 3 mm skin punch biopsy, a blood sample, or a urine sample) collected under sterile conditions. The samples will be used to derive somatic cells, which will then be reprogrammed into iPSCs and differentiated into β cells for laboratory analyses.\n\nParticipants will:\n\nUndergo a one-time sample collection (skin biopsy, blood draw, or urine collection) at Ospedale San Raffaele\n\nReceive standard post-procedure care (if applicable)\n\nThis research aims to improve understanding of β cell function and dysfunction in diabetes and to advance personalized regenerative therapies for β cell replacement.",[28],"Diabetes",[30],"diabetes; stem cells, induced pluripotent stem cells","RECRUITING","2026-03-13",{"date":34,"type":35},"2026-03-18","ACTUAL",{"date":37,"type":22},"2026-03-01",{"date":39,"type":22},"2036-02-28",{"name":41,"class":42},"Ospedale San Raffaele","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100586967","personalizing-adoptive-cell-transfer-for-solid-tumors-towards-a-new-patient-tailored-treatment-option-100586967","NCT06922266","Personalizing Adoptive Cell Transfer for Solid Tumors: Towards a New Patient-tailored Treatment Option","Chewbacca","Inclusion Criteria:\n\n* Participant is willing and able to provide informed consent for participation in the study.\n* Age: Adults aged 18 years or older.\n* Diagnosis: non-small cell lung cancer (Stage I-II, III), with or without lymph node involvement, ideally with sufficient tumor burden to provide adequate tissue for analysis. In accordance with good clinical practice, patients with early-stage disease will undergo direct surgery, whereas patients with advanced-stage disease will receive neoadjuvant treatment followed by surgery.\n* Ability to attend scheduled follow-up visits, if applicable, for additional peripheral blood sample collection during treatment.\n\nExclusion Criteria:\n\n* Presence of any active infection or underlying condition that could compromise the safety of tissue and blood sampling.\n* Prior history of another malignancy that might interfere with data interpretation related to non-small cell lung cancer progression and immune response.\n* Any current use of immunosuppressive medications (e.g., high-dose steroids) which might alter immune response assessments, except as part of non-small cell lung cancer treatment.\n* Pregnancy and breastfeeding","18 Years",{"count":53,"type":22},20,"4 Years","OBSERVATIONAL","This is a monocentric prospective observational study. This study will include patients with a diagnosis of non-small cell lung cancer for the collection of blood and tissue specimens.",[58],"Carcinoma, Non-Small-Cell Lung",[60,61,62,63],"Immunotherapy","Precision Oncology","Lung cancer","Adoptive Cell Transfer","NOT_YET_RECRUITING","2025-04-03",{"date":67,"type":35},"2025-04-10",{"date":69,"type":22},"2025-05-01",{"date":71,"type":22},"2029-04-30",{"name":41,"class":42},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":43},"100557724","predicting-the-risk-of-diabetic-neurodegenerative-disorders-by-artificial-intelligence-tools-based-on-retinal-imaging-100557724","NCT06541834","Predicting the Risk of Diabetic Neurodegenerative Disorders by Artificial Intelligence Tools Based on Retinal Imaging","Predicting the Risk of Diabetic Neurodegenerative Disorders by Artificial Intelligence Tools Based on Retinal Imaging-DINEURET (PNRR-MCNT2-2023-12378367)","Inclusion Criteria:\n\n1. Male or female \\> 45 years-old;\n2. Diagnosis of type 2 DM;\n3. No previous treatment for diabetic retinopathy;\n4. Clear ocular media;\n5. Ability to communicate well with the Investigator and to understand and comply with the requirements of the study;\n6. Ability to provide written informed consent in accordance with institutional, local and national regulatory guidelines and to attend all study visits\n\nExclusion Criteria:\n\n1. Patients affected by other retinal disease than diabetic retinopathy;\n2. Presence of diabetic macular edema;\n3. Presence of proliferative diabetic retinopathy;\n4. Any media opacities, including corneal opacity, cataract formation and hemorrhage in the vitreous body, which may interfere with viewing by the laser surgeon of the target structures in the study eye(s). Subject requiring cataract surgery in the next 12 months must be excluded;\n5. Aphakic eye(s) with vitreous in the anterior chamber;\n6. Neovascular glaucoma;\n7. Glaucoma caused by congenital angle anomalies;\n8. Open angle of less than 90º or extensive peripheral anterior and low synechia, present circumferentially around the corner;\n9. Glaucoma secondary to active uveitis;\n10. Any other ocular condition that would progress in the study period and confound visual acuity assessment a part from diabetic retinopathy;\n11. Presence of idiopathic or autoimmune-associated uveitis;\n12. Any ocular or systemic medication known to be toxic to the lens, retina or optic nerve;\n13. Any intra-ocular surgery on a qualifying eye within three months prior to entry in the study;\n14. Any prior thermal laser in the macula or intravitreal injections or panphotocoagulation;\n15. History of vitrectomy, filtering surgery, corneal transplant or retinal detachment surgery;\n16. Previous therapeutic radiation in the ocular region in either eye;\n17. Participation in an investigational drug, biologic, or device study within 6 months prior to baseline \\[Note: observational clinical studies solely involving over-the-counter vitamins, supplements, or diets are not exclusionary\\];\n18. Has a serious medical illness that will prevent the subject from performing study activities (including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease) or, in the judgement of the Investigator, is likely to require surgical intervention or hospitalization at any point during the study;\n19. In the opinion of the Investigator, is unlikely to comply with the study protocol.","45 Years",{"count":82,"type":22},250,"Diabetic Retinopathy (DR) is the most frequent complication of diabetes, and its presence and severity are related to the appearance of both micro and macrovascular events.\n\nRisk profiles have been suggested as a major direction for research in diabetes, based on non- invasive retinal imaging evaluations. There has been promising evidence that artificial intelligence (AI) based on fundus photographs can detect clinical metrics and systemic conditions invisible to expert human observers. Notably, deep-learning (DL) convolutional neural networks (CNNs) developed for retinal photographs have been shown superior performance in the detection of DR compared with human assessment.\n\nThe relationship between retinal vascular abnormalities and neurovascular complications of diabetes has been reported. The retina is a window to the body that allows a non-invasive observation of microvascular and neural tissues. However, in clinical practice there are no reported phenotypic indicators or reliable examinations to identify type 2 diabetic (T2D) patients with neurodegenerative\u002Fcognitive impairment. The presence of cognitive Impairment is a very frequent complication in diabetic patients, reported up to 60% of the diabetics when compared to only 11 % in the non-diabetics (OR of 8.78).\n\nFurthermore, AI based on retinal imaging has never been applied before to predict the onset and worsening of neurodegenerative\u002Fcognitive impairment of T2D in a real-world setting.\n\nThe aim of this project is to develop trustworthy AI tools for predicting the risk of developing and progressing of neurodegenerative\u002Fcognitive diabetic impairment based on retinal images, in T2D population. For the development and validation of these tools, T2D patients will be enrolled from 4 well-established Italian centers.\n\nThe proposal of this study is addressed to health care systems, in order to improve their consciousness about diabetic neurodegenerative\u002Fcognitive complications and reduce the related economic burden. Since the huge majority of these disorders remain undiagnosed, DINEURET will provide new cost-effective screening strategies to identify these patients.\n\n4 centers will be involved:\n\n* 75 patients will be included in the IRCCS Ospedale San Raffaele, Milan;\n* 75 patients will be included in the IRCCS MultiMedica, Milan;\n* 50 patients will be included in the Ospedale Della Murgia \"Fabio Perinei\", Altamura;\n* 50 patients will be included in the Azienda Ospedaliero-Universitaria (AOUI) of Cagliari, Cagliari.",[85,86],"Diabete Mellitus","Cognitive Impairment","2025-03-11",{"date":89,"type":35},"2025-03-14",{"date":91,"type":35},"2024-08-30",{"date":93,"type":22},"2026-08-30",{"name":41,"class":42},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":102,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":112,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},"100427563","subthreshold-laser-treatment-for-reticular-pseudodrusen-secondary-to-age-related-macular-degeneration-100427563","NCT04847635","Subthreshold Laser Treatment for Reticular Pseudodrusen Secondary to Age-related Macular Degeneration","PASCAL-RPD","Inclusion Criteria:\n\n* 50 years or older\n* Presence of RPD secondary to AMD\n* Best-corrected visual acuity (BCVA) between 20\u002F20 and 20\u002F400 inclusive\n* Clear ocular media\n* Ability to provide informed consent and attend all study visits\n\nExclusion Criteria:\n\n* Presence of Geographic Atrophy (GA)\n* Evidence of choroidal neovascularization in either eye\n* Any prior treatment for AMD, aside from antioxidants\n* Any corneal opacity, cataract formation and hemorrhage in the vitreous body, which may interfere with viewing by the laser surgeon of the target structures\n* Aphakic eye with vitreous in the anterior chamber\n* Neovascular Glaucoma\n* Glaucoma caused by congenital angle anomalies\n* Open angle of less than 90º or extensive peripheral anterior and low synechia, present circumferentially around the corner\n* Significant corneal edema or reduced water clarity that obscures the view angle in detail\n* Glaucoma secondary to active uveitis\n* Any other ocular condition that would progress in the study period and confound visual acuity assessment\n* Any ocular or systemic medication known to be toxic to the lens, retina or optic nerve Presence of idiopathic or autoimmune-associated uveitis\n* Any intraocular surgery 3 months of entry\n* Any prior thermal laser in the macula\n* History of vitrectomy, filtering surgery, corneal transplant or retinal detachment surgery\n* Previous therapeutic radiation in the ocular region in either eye\n* Any treatment with an investigational agent in the previous 60 days before study entry\n* Women of child-bearing potential, defined as all women less than 1 year postmenopausal or less than 6 weeks since sterilization (further definition can be found in Section 12.7) at Baseline, unless they are using highly effective methods of contraception during dosing of study treatment.\n* Participation in an investigational drug, biologic, or device study within 6 Months prior to Baseline \\[Note: observational clinical studies solely involving over-the-counter vitamins, supplements, or diets are not exclusionary","55 Years",{"count":104,"type":22},50,[25],"Prospective, randomized, controlled, longitudinal, interventional multicentric study involving patients with reticular pseudodrusen secondary to AMD.\n\nThe objective of this study is to establish the effectiveness of subthreshold laser treatment in increase\u002Fprevent the decrease of the retinal sensibility in patients with reticular pseudodrusen, and to reduce the progression of RPD to atrophy.\n\nApproximately 50 naïve patients with reticular pseudodrusen who underwent subthreshold laser treatment in perifoveal area. These patients should be randomized in the 2 study arms of the study. Patients will be evaluated at Screening\u002FBaseline and then revaluated and retreated at month 3, 6 and 9. At month 12, all patients will be evaluated with a full ocular examination, visual acuity measurement (VA), optical coherence tomography (OCT) with autofluorescence, OCT-angiography and microperimetry.\n\nThe rationale of the study is to prevent the evolution of reticular pseudodrusen to atrophic degeneration.",[108,109,110,111],"Macular Degeneration, Senile","Laser Burn of Retina","Macular Degeneration Intermediate","Macular Degeneration, Dry",[113,114,115,116],"Retina","Age-related macular degeneration","Reticular pseudodrusen","Sub-threshold laser",{"date":118,"type":35},"2025-03-12",{"date":120,"type":35},"2021-03-16",{"date":122,"type":22},"2026-09-01",{"name":41,"class":42},3,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":43},"100547860","identification-of-new-biological-markers-for-the-progression-of-mycobacterium-abscessus-induced-lung-disease-in-cystic-fibrosis-100547860","NCT06413459","Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis","BioMol-MA","Inclusion Criteria:\n\n* Patients with a certain diagnosis of cystic fibrosis and visited during normal clinical practice, in accordance with the standard operating procedures in force at the Centres.\n* Both sexes\n* Age \\>18 years\n* Obtaining informed consent for patients (based on the procedures established by the protocol).\n\nExclusion Criteria:\n\n* Patients unable to understand the instructions and information provided and be able to adequately accept the study methods.",{"count":133,"type":22},40,"In this project the investigators aim to identify new biological markers by characterizing the response\u002Finflammation associated with the development and progression of M. abscessus lung disease in patients suffering from cystic fibrosis with the aim of increasing current knowledge available on the development and progression of lung disease.",[136,137],"Non-Tuberculous Mycobacterial Pneumonia","Cystic Fibrosis Lung",[139],"scRNASec","2024-05-14",{"date":142,"type":35},"2024-05-16",{"date":144,"type":35},"2021-04-08",{"date":146,"type":22},"2027-03-30",{"name":41,"class":42},{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":157,"conditions":158,"keywords":167,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":43},"100548112","genetics-in-the-progression-of-nephropathies-100548112","NCT06416761","Genetics in the Progression of Nephropathies","The Genetic Contribution to Progression of Kidney Disease","Inclusion Criteria:\n\n. presence of specific renal disease\n\nExclusion Criteria:\n\n* to be evaluated in the different sub-protocols",{"count":156,"type":22},10000,"This study evaluates the role of genetic in the development and progression of different nephropaties with particular attention to:\n\n* AKI\n* CKD\n* Hypertension\n* ADPKD\n* CKD-MBD\n* Patients with decompensated heart failure undergoing either medical or surgery therapy\n* Patients with hematologic cancer exposed to chemotherapeutic agents or undergoing allogeneic bone marrow transplantation\n* glomerular diseases",[159,160,161,162,163,164,165,166],"AKI","CKD","Ckd-Mbd","CKD (Chronic Kidney Disease) Stage 5D","ADPKD","Hypertension","Hematologic Malignancy","Bone Marrow Transplant Complications",[168,169,170,171,172,173],"genetic in hypertensive kidney disease","salt intake in BP control and CKD progression","genetic in CKD","endogenous Ouabain as marker of AKI","protein intake restriction in CKD progression","hypertension in allogenic bone marrow transplantation","2024-05-11",{"date":142,"type":35},{"date":177,"type":35},"2006-05-19",{"date":179,"type":22},"2041-05-19",{"name":41,"class":42},{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":192,"conditions":193,"keywords":196,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":124},"100285508","annuloplasty-for-not-severe-tr-in-patients-undergoing-mv-repair-versus-mitral-repair-only-nostrum-100285508","NCT02996552","Annuloplasty for Not-Severe TR in Patients Undergoing MV Repair Versus Mitral Repair Only (NOSTRUM)","Annuloplasty for the Treatment of Not-Severe Tricuspid Regurgitation in Patients Undergoing Surgery for Mitral Valve Disease: a Prospective, Spontaneous, Multicentre, Randomized Study","NOSTRUM","Inclusion Criteria:\n\n* age \\> 18 years;\n* ability to provide informed consent;\n* patients scheduled for mitral valve regurgitation\n* TR ≤ 2+ with annular dilation\n* Tricuspid diastolic diameter ≥ 40 mm or 21 mm\u002Fm2\n\nExclusion Criteria:\n\n* patient's refusal\n* non-elective cardiac surgery;\n* organic disease of tricuspid valve\n* TR≥3",{"count":190,"type":22},142,[25],"The surgical treatment of less than severe (≤2+\u002F4+) functional tricuspid regurgitation (TR) in patient undergoing mitral valve surgery, is still controversial: some observational studies have suggested that performing tricuspid annuloplasty in patients undergoing mitral valve surgery with a dilated tricuspid annulus, and TR≤2+ may provide a clinical benefit, while in other observational studies such benefit has not been documented.\n\nThe ESC Guidelines assign the class IIa recommendation for surgical treatment in patients with tricuspid regurgitation ≤2+ and a dilated annulus, if surgery is concomitant to the repair or replacement of the mitral valve. However the level of evidence C (expert opinion) confirms the absence of clear scientific evidence to support this recommendation.\n\nIt is therefore very important to carry out randomized trials designed to really prove the supposed efficacy of prophylactic tricuspid annuloplasty, especially in patients with degenerative etiology where the data are particularly controversial.\n\nThe aim of the study will be to establish the effectiveness of the tricuspid annuloplasty in the early stage of TR. The investigators enrolled patients with TR≤2+ and annular dilation undergoing mitral valve repair.\n\nPrimary end-point will be the freedom from recurrence of TR≥3+ and from progression of 2 degrees of TR compared to pre-operative, at discharge and 12 months after surgery, assessment by transthoracic echocardiography. Secondary endpoints are to demonstrate the superiority of combined treatment (M \\& T Repair Group) compared to single treatment (Mitral-Only Group) at 5 and 10 years after surgery.\n\nThis will be an experimental superiority, prospective, spontaneous, multicenter, randomized trial.\n\nPatients will be randomly assigned to two parallel arms with an allocation ratio 1:1 stratified by center, to receive mitral repair only (Mitral-Only group) or both mitral and tricuspid repair (M \\& T Repair group).",[194,195],"Tricuspid Disease","Mitral Regurgitation",[197,198],"Tricuspid annulus dilation","mitral valve regurgitation","2020-07-20",{"date":201,"type":35},"2020-07-21",{"date":203,"type":35},"2011-06-08",{"date":205,"type":22},"2030-12",{"name":41,"class":42},""]